Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study
Background: Currently, there is contradictory evidence regarding the best strategy to follow after discontinuation of a first biological agent in patients with rheumatoid arthritis (RA). We aimed to compare the long-term efficacy of switching to a second tumor necrosis factor inhibitor (TNFi) versus...
Guardado en:
Autores principales: | Patricia Bogas, Chamaida Plasencia-Rodriguez, Victoria Navarro-Compán, Carolina Tornero, Marta Novella-Navarro, Laura Nuño, Ana Martínez-Feito, Borja Hernández-Breijo, Alejandro Balsa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/37304551fe53486ea600c139c7bab59b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rheumatoid arthritis: Disease or syndrome?
por: Jessica A Stanich, et al.
Publicado: (2009) -
Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis
por: Takahashi R, et al.
Publicado: (2014) -
Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis
por: Peter BB Jones, et al.
Publicado: (2010) -
Genetics of rheumatoid arthritis: GWAS and beyond
por: McAllister KM, et al.
Publicado: (2011) -
Update on the use of rituximab for intractable rheumatoid arthritis
por: R John Looney
Publicado: (2009)